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Abstract: Fluorescein isothiocyanate-conjugated bovine serum albumin (FITC-BSA)-loaded 
polyethylene glycol (PEG)-modified liposomes and lipoparticles with high protein entrapment 
were developed. The lipid formula of the liposomes contained PEGylated lipids and unsaturated 
fatty acids for enhancing membrane fluidity and effective delivery into cells. The preparation 
techniques, lipid content, and PEG-modified lipoparticle ratios were evaluated. The PEG-modified 
lipoparticles prepared by ethanol injection extrusion (100 nm pore size) achieve a population 
of blank liposomes with a mean size of 125 ± 2.3 nm and a zeta potential of −12.4 ± 1.5 mV . 
The average particle size of the PEG-modified lipoparticles was 133.7 ± 8.6 nm with a zeta 
potential of +13.3 mV . Lipoparticle conformation was determined using transmission electron 
microscopy and field-emission scanning electron microscopy. The FITC-BSA encapsulation 
efficiency was dramatically increased from 19.0% for liposomes to 59.7% for lipoparticles. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) results confirmed 
the preparation process, and an 8-hour leaching test did not harm the protein structure. Once 
prepared, the physical and chemical stability of the PEG-modified lipoparticle formulations 
was satisfactory over 90 days. In vitro retention tests indicated that the 50% retention time for 
the protein-containing lipoparticles was 7.9 hours, substantially longer than the liposomes at 
3.3 hours. A Caco-2 cell model was used for evaluating the cytotoxicity and cell uptake efficiency 
of the PEG-modified lipoparticles. At a lipid content below 0.25 mM, neither the liposomes 
nor the lipoparticles caused significant cellular cytotoxicity (P , 0.01) and FITC-BSA was 
significantly taken up into cells within 60 minutes (P , 0.01).
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Introduction
Liposomes, solid nanoparticles, and many other nanoparticulate carriers have 
demonstrated biological properties that make them excellent pharmaceutical 
  delivery systems.1–4 In particular, liposomes are well recognized as pharmaceutical 
carriers because of their biocompatibility, biodegradability, and low toxicity and are 
  clinically used for efficacy enhancement and toxicity reduction.5,6 Liposomes have 
good   longevity in the blood that allows their accumulation in pathological areas 
with compromised vasculature, can demonstrate specific targeting to disease sites 
when various targeting ligands are attached to their surface to enhance intracellular 
penetration, possess   stimulus-sensitivity allowing for drug release from the carriers 
under certain pathological conditions, and show contrast properties with loading of 
various contrast materials that allows for direct visualization in vivo.7–9International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Liposomes have been the hallmark of lipid-based nano-
particles for site-specific delivery of drugs and pharma-
ceuticals. However, Tiwari et al10 reported novel gel core 
liposomes, prepared with bovine serum albumin (BSA), and 
found these to be an effective tool for immunization. There 
is a need to develop alternate nanoparticles to improve their 
stability, and lipid mixtures composed of colloidal assemblies 
(ie, lipoparticles) are of great interest in biotechnology 
and biomedicine. This mixture of polymer and lipid-based 
delivery system contains a core polymer, which serves as 
a functional skeleton and provides mechanical support to 
vesicles. It is hoped that these drug carriers may allow for 
better control over drug release and delivery of therapeutics 
that do not efficiently load into liposomes. Lipoparticles are 
stabilized liposomes with all the advantages of liposomes (ie, 
cell membrane mimicking, targeting, controlled release, and 
cell-specific interactions), and with increased stability and 
the added advantage of controlled release over a prolonged 
period of time. Compared with other drug-delivery systems, 
lipoparticles have only been developed recently and are 
potentially attractive and marketable choices due to their 
natural components and ease of large-scale production.11
PEGylated lipoplexes are delivered to cells, but the 
ability to mediate successful transfection is hampered by 
their PEGylation.12 The potential of formulating dioleoyl 
trimethylammonium  propane  (DOTAP)/cholesterol 
lipoplexes with polyethylene glycol (PEG)-modified lipids 
would confer the shielding and stabilizing properties of PEG 
to the particles in the bloodstream.13,14 Medium-chain fatty 
acids (MCFAs; an eight-carbon medium-chain fatty acid) and 
decanoic acid (a ten-carbon medium-chain fatty acid) have 
physical and metabolic properties that are distinct from those 
of long-chain fatty acids that make them a readily available 
cellular energy source. In animals, MCFAs are absorbed via 
the portal vein system, which is in contrast to long-chain fatty 
acids, which are absorbed via the lymphatic system. After 
incorporation into cells, MCFAs are secreted and transported 
via the portal vein to the liver. These properties have been 
used advantageously in clinics for more than 50 years for 
treating lipid absorption disorders, undernourished patients, 
and more recently, subjects with long-chain fatty acid 
oxidation defects.15–17
For pharmaceutical development and clinical use, several 
criteria must be fulfilled in terms of size as well as chemical 
and physical stability. Small-sized liposomes have several 
advantages as drug delivery systems. Although designed lipo-
somes can be made by selecting an appropriate composition 
and production method to achieve a suitable size and size 
distribution, the effect on drug loading, biodistribution, 
targeting, therapeutic efficacy, and rate of clearance from 
the body are of critical importance for in vivo applications 
of liposomal formulations.18 Several techniques have 
been reported in the literature for liposome preparation. 
The   conventional ethanol injection technique offers the 
advantage of simplicity, the absence of potentially harmful 
chemicals, formation of small-sized liposomes without any 
physical treatments, minimal technical requirements, and the 
  possibility of large-scale production.19,20 This is especially 
true for products based on the ethanol-injection technique 
that use a membrane contactor module specifically designed 
for colloidal system preparation, and such scalable liposomal 
preparation techniques are suitable for the entrapment of 
pharmaceutical agents into liposomes.21
It is known that a homogeneous population of small lipo-
somes represents the best formulation for drug delivery. Thus, 
from the preparative point of view, we looked for a particular 
system that was able to reproducibly generate a relatively 
narrow distribution of small lipoparticles. However, ordi-
nary liposomes exist in liquid form, which leads to several 
problems resulting in instability, such as particle aggregation/
sedimentation, phospholipid oxidation/decomposition, and 
drug leakage. Furthermore, the process used for liposome 
preparation must be reproducible, and the process conditions 
must allow production at reasonable cost, and economic 
scale-up.22 Therefore, our prepared lipoparticles were freeze-
dried so that these problems could be avoided.23
In this paper, we show that lipoparticle drug formulations 
could be prepared in situ by preparing lipoparticles containing 
a core of biocompatible protamine with protein within a 
phospholipid bilayer, in an effort to overcome the limitation 
of instability and early release of entrapped bioactives. These 
particles were formed using an ethanol-injection technique, 
followed by a membrane contactor method optimized by 
means of various in vitro studies. Several parameters must 
be optimized in order to obtain a suitable final formulation, 
and this paper is devoted to such an investigation. Firstly, 
we studied liposome formulation stability, using the omega-3 
fatty acid docosahexaenoic acid (DHA) to modulate 
membrane fluidity, distearoyl phosphoethanolamine-PEG2000 
to improve shielding and stabilizing, as well as the organic 
and aqueous phases content as a function of the lipid con-
centration and composition. Products were analyzed by size 
distribution, as determined by dynamic light scattering and 
zeta potential. Secondly, by focusing on preparation methods, 
we showed that it is possible to obtain monomodal size 
distributions of rather small vesicles. In order to enhance the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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stability of MCFA lipoparticles, strengthen their functional 
effect, and expand their application domain, lyophilized 
lipoparticles were prepared, and these could be directly used 
via injection or aerosol after rehydration. The preparation 
techniques influenced the size, encapsulation efficiency, 
and in vitro retention profiles. The optimized formulation 
was further evaluated for protein structural stability by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and for cell cytotoxicity in Caco-2 cells. We 
expect that novel lipoparticle carrier systems will have the 
potential to be applied in drug delivery and clinical therapy 
to protect the biological activity of proteins and peptides 
as well as increase efficacy and decrease the occurrence of 
side effects.
Materials and methods
Materials
Fluorescein isothiocyanate-conjugated bovine serum 
albumin (FITC-BSA), cholesterol, cis-4,7,10,13,16,19-
docosahexaenoic acid (DHA), D-(+)-trehalose dihydrate, 
n-hexane, and protamine sulfate salt from salmon (Grade X), 
were obtained from Sigma-Aldrich (St Louis, MO). TritonX-
100 was purchased from Calbiochem-Behring (La Jolla, 
CA). 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 
was purchased from Avanti Polar Lipids (Alabaster, 
AL). N-(carbony-methoxypolyethyleneglycol 2000)-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine, sodium 
salt (DSPE-PEG2000) was purchased from NOF Corpora-
tion (Tokyo, Japan). WST-1 cell proliferation reagent was 
obtained from Clontech Laboratories (Mountain View, CA). 
Dulbecco’s Modified Eagle Medium (DMEM), antibiotic 
solutions (100 IU/mL penicillin and 100 µg/mL strepto-
mycin), fetal bovine serum (FBS), and phosphate buffer 
saline (PBS) were supplied by Gibco BRL (Corning, NY). 
Ultrapure water was obtained with Milli-Q equipment 
(Millipore, Billerica, MA). All other chemicals and reagents 
used were of analytical purity or higher quality and obtained 
commercially.
Preparation of liposomes
Liposomes were prepared by an ethanol injection method 
modified from a previous report.12 Briefly, varied molar 
ratios of DSPC/cholesterol/ DSPE-PEG/DHA were melted 
in a 60°C water bath, and the lipid mixture was then dis-
solved in the proper alcohol solvent and rapidly injected 
at room temperature with a one-way, 1 mL syringe into a 
dispersant water solution. The dispersion was extruded ten 
times through a polycarbonate membrane (100 nm pore size) 
using an extruder (Avanti Polar Lipids, Mini-Extruder). The 
various ratios of lipid content/ethanol/water (L/E/W) were 
evaluated. The total lipid concentration of the prepared 
liposomes was 0.15 mM.
FITC-BSA, if present, was dissolved in the alcohol lipid 
solution, and the correct aliquot of this solution was injected 
as described above. Every FITC-BSA-containing preparation 
was kept in amber glassware to avoid exposure to light. 
Solutions were always freshly prepared before use.
Preparation of lipoparticles
Solid cores were prepared using a physical mix method. 
Briefly, FITC-BSA and protamine sulfate were freshly 
  dissolved in ethanol. The weight ratio of protamine sulfate/
FITC-BSA (20/1) solution was added and mixed. An FITC-
BSA/protamine sulfate core was dissolved in the alcohol lipid 
solution; the correct aliquot of this solution was injected as in 
the liposome preparation process described above. Untrapped 
FITC-BSA and protamine sulfate from the lipoparticles were 
removed by ultracentrifugation at 25,000 g for 15 minutes 
(CPMax-100; Hitachi, Tokyo, Japan) and further dialyzed 
against 800 mL distilled water for 12 hours at 4°C to remove 
untrapped FITC-BSA from the lipoparticle vesicles.
Preparation of freeze-dried lipoparticles
D-(+)-trehalose dihydrate was used alone as a cryoprotectant 
in the lipoparticles, with cryoprotectant and lipoparticles at a 
ratio of 4:1 (w/w). The lipoparticle suspensions prepared by 
ethanol injection, with extraction using a 100 nm membrane, 
were added to the D-(+)-trehalose dihydrate under optimal 
conditions and were then filtered using a 0.45 µm filter 
(Millipore, Boston, MA). Using deep-freeze equipment, the 
lipoparticle suspensions were prefrozen for 6 hours, reaching 
a terminal temperature of −80°C, and then dried at −86°C at 
0.1 mbar for 48 hours in a vacuum freeze-drying system. The 
freeze-dried FITC-BSA-loaded lipoparticles were evaluated 
in terms of vesicle size, zeta potential, protein stability, and 
in vitro release.
size and zeta-potential analysis
The prepared particles (liposomes or lipoparticles) were 
diluted to 1 mM using an appropriate volume of sterile 
PBS (pH 7.3). The weight-average hydrodynamic diameter 
of the various particles was determined by a dynamic 
light-scattering method using a particle analyzer (LB-500; 
Horiba, Tokyo, Japan) at room temperature. Four measure-
ments were performed for each sample. The zeta potential 
(ζ) of the particles was measured by determining the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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electrophoretic mobility using a zeta potential analyzer 
(Zeta Plus; Brookhaven Instruments, Holtsville, NY) at 
room temperature. Four measurements were performed for 
each sample.
Morphological investigation
Particle suspensions were imaged using transmission electron 
microscopy (TEM) (JSM-1200EXII; JEOL, Tokyo, Japan). 
A drop of the particle suspension was placed onto a carbon-
coated copper grid from Ted Pella (Redding, CA), forming a 
thin liquid film. The films were negatively stained with a 2% 
phosphotungstic acid solution (w/w; pH 7.1) for 1 minute. 
The excess of the phosphotungstic solution was removed with 
filter paper, and stained samples were characterized using an 
accelerating voltage of 80 kV . The images were examined 
using a TEM at 75 kV . The morphology of the lipoparticles 
was examined using field emission-scanning electron micros-
copy (FE-SEM; JSM 6500F; JEOL). The SEM samples 
were mounted on a carbon adhesive tab and sputter coated 
(10–15 nm) with gold palladium (60/40 alloy).
stability study
Stability was assessed by comparing changes in mean diam-
eters, zeta potential, and protein activity of one liposome 
and two lipoparticle formulations. The particle suspension 
and its freeze-dried powder were stored away from light at 
4°C for different periods of time. The ability of vesicles to 
retain protein activity was assessed by varying the preparation 
process, final product, and release times. At different stages, 
the samples were withdrawn periodically and analyzed for 
residual protein activity. Protein integrity was also evaluated 
by SDS-PAGE.
standard curve generation
We prepared a series of 10 µL reference solutions that were 
measured using a fluorometer, and determined the peak areas. 
The regression equations were then obtained with the   content 
of the FITC-BSA peak area as ordinate. The regression 
equations were as follows: y = 0.2654x + 0.0520, R = 0.9998 
for water solution. The results of linearity show that the 
peak areas were linearly related to the sample concentration 
within the range of 1.0 and 40 µg/mL; y = 2.2473x + 0.0319, 
R = 0.9998 for the PBS solution; the peak areas were linearly 
related to the sample concentration within the range of 0.01 
and 0.4 µg/mL; y = 0.0253x + 0.0327, R = 0.9998 for the 
n-hexane extracted solution; and the peak areas were linearly 
related to the sample concentration within the range of 0.1 
and 8.0 µg/mL.
Encapsulation efficiency
Particle encapsulation efficiency was determined based 
on the amount of entrapped drug (ie, FITC-BSA) using a 
dialysis method. Dialysis bags were soaked before use in 
distilled water at room temperature for 12 hours to remove the 
  preservative, followed by rinsing thoroughly in   distilled water. 
Briefly, a volume of the drug-loaded particle sample (V) was 
loaded in a dialysis device of 1000 kDa molecular weight cut-
off (MWCO) (Spectra/Por; Spectrum Laboratories,   Rancho 
Dominguez, CA) with 150 mL distilled water at 4°C in 
order to separate the unloaded drug. The   particles were then 
dissolved in n-hexane in order to analyze the encapsulated 
amount of drug (Edrug). The drug   encapsulation efficiency 
(EE%) was calculated as the percentage of the encapsulated 
amount (Edrug) relative to the initial theoretical amount 
(Tdrug), as in the following equation:
  EE% = (Edrug/Tdrug) × 100
In vitro retention test
In vitro release of FITC-BSA from the particles was deter-
mined using a dialysis device with a 1000 kDa MWCO 
in 150 mL of PBS (pH 7.4) at 36°C following the method 
published previously.24 Three dialysis devices were pre-
pared containing free FITC-BSA (control), FITC-BSA in 
liposomes, and FITC-BSA in lipoparticles. An accurately 
measured amount of various particle formulations was 
transferred to the dialysis bags and placed in a receiving 
compartment containing 120 mL PBS (pH 7.4). Control 
bags were prepared and tested in parallel. Each control bag 
contained 0.1 mg FITC-BSA. The two ends of the dialysis 
bag were tightly bound with thread. The bags were hung 
inside a conical flask with the help of a glass rod so that 
the portion of the dialysis bag containing the formulation 
dipped into the buffer solution. The flask was kept on a 
magnetic stirrer, and stirring was maintained at 100 rpm 
at 36°C with thermostatic control. At predetermined time 
intervals the release medium was withdrawn for analysis. 
By adjusting the concentration of FITC-BSA to the linear 
range, the amount of released FITC-BSA from the particle 
was analyzed using a fluorometer. An excitation wavelength 
of 488 nm and emission wavelength of 522 nm were used to 
observe the fluorescence intensity of FITC-BSA. The FITC-
BSA retained in the particles was calculated by subtracting 
the initial amount of FITC-BSA in the particles from the 
amount at the time of release. To analyze the release kinetics 
and mechanisms, data were fitted to the three following 
mathematical models.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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1.   Zero order
Mt/M∞ = ko t
2.   First order
Mt/M∞ = 1-exp(-k1 t)
3.   Higuchi model25
Mt/M∞ = kh t1/2
where Mt/M∞ is the fraction of drug released at time t and 
ko, k1, and kh represent the zero-order release constant, first-
order release constant, and Higuchi constant, respectively. 
The constants are related to the structural and geometric 
  characteristic of the device, and are indicative of the drug 
release mechanism. The values of ko, k1, and kh were 
determined by fitting the release data into the respective 
equations.
Protein stability test
The prepared particles were incubated in PBS for 4 and 
8 hours and then analyzed using SDS-PAGE. About 0.1 mL 
of 100 µg/mL of protein sample was mixed with 25 mL of 
Laemelli’s buffer (BioRad, Hercules, CA) and boiled for 
5 minutes. The samples were then subjected to electropho-
resis at 40 mA in a vertical slab Ready Gel (12%; BioRad). 
Proteins were visualized using a silver staining kit (BioRad). 
The density of the protein bands in the gel was analyzed 
using GelExpert software (Nucleotech, San Mateo, CA). 
The areas of the bands were kept constant for the different 
gels, and the intensity of the bands was normalized to the 
background of each gel.
Cell culture
The established human epithelial colorectal adenocarcinoma 
cell line Caco-2 was obtained from the American Type 
Culture Collection (Rockville, MD). Caco-2 cells were 
routinely grown in cultured DMEM supplemented with 100 
IU/mL penicillin, 100 mg/mL streptomycin, 1% nonessen-
tial amino acids, and 20% fetal bovine serum in 5% CO2 at 
37°C. The cells were then seeded into flat-bottom 96-well 
tissue culture plates (Greiner Labortechnik, Frickenhausen, 
Germany) for cell toxicity assays or into 8-well Lab-Tek 
II Chamber Slides (Nalge Nunc, Elkhart, IN) for in vitro 
  cellular uptake studies.
In vitro cell viability/cytotoxicity studies
The effect of the particles on cytotoxicity was evaluated using 
a commercial colorimetric WST-1 cell proliferation assay 
(BioChain Institute, Hayward, CA). The WST-1 assay is a 
simple nonradioactive colorimetric assay for measuring cell 
cytotoxicity, proliferation, and viability. Aqueous particle 
suspensions at final concentrations of 2.5, 0.25, 0.025, and 
0.0025 mg/mL were obtained by dispersing the dry particles 
in water with the aid of an ultrasonicator (40 kHz, 25°C). 
Cells (1.0 × 105 cells/mL) were seeded into 96-well tissue 
culture plates in 100 µL of culture medium, allowed to adhere 
for 5 hours, and serum starved in 0.1% BSA in DMEM for 
24 hours prior to use. A total of 5 µL of various concentra-
tions of sample were added to each well, and the cells were 
incubated for 72 hours at 37°C. Subsequently, 5 µL of WST-1 
(5 µg/mL) was added to each well for 1 hour at 37°C before 
terminating the incubation. Cells were washed and incubated 
with 100 µL of variously diluted nanoparticles in 0.1% BSA-
DMEM solution for various times at 37°C. Absorbance (Abs) 
was measured at 450 nm using a spectrophotometer. Cell 
cytotoxicity was calculated using the following formula: cell 
cytotoxicity (%) = 1 – [(Abs of treated cells)/(Abs of control 
untreated cells)] × 100. The viability of cells left untreated 
was normalized to 100%. Six experimental sets were carried 
out, and each set was performed in triplicate.
Flow cytometry
Caco-2 cells were seeded into 8-well plates in DMEM at 
a cell density of 3 × 104 cells per well and incubated for 
24 hours to achieve 75% confluence. Before the uptake study, 
the culture media was removed and the cells were washed 
with PBS. FITC-BSA-loaded particles in 1 mL of serum-
free culture media were then added. At different times, the 
cells were washed three times with PBS and then detached 
using 0.05% trypsin/0.02% EDTA, washed with PBS, and 
resuspended in 1 mL PBS for flow cytometric analysis. The 
uptake of FITC-BSA-loaded particles was measured using 
a flow cytometer (FACScan; Becton Dickinson, Heidelberg, 
Germany). The cells were analyzed using 488 nm excitation 
and 522 nm band-pass filters in the emission path. Forward 
and side light scatter was used to gate the desired scattered 
events of normal cells from dead cells and cell debris.
In vitro cellular uptake studies
It has been shown that the addition of FITC-BSA expresses 
various integrins and serves as an in vitro cell model for 
protein delivery.26 To determine the delivery efficiency, 
we determined the uptake of particles by Caco-2 cells.27 
Briefly, cells were seeded into 8-well plates at a density 
of 1 × 105 cells per well in 1 mL of complete medium 
and incubated for 24 hours prior to the uptake study. The 
media was then replaced with fresh growth medium in 
each well. A total of 200 µL of FITC-BSA-loaded particle International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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suspensions (0.01 mg/mL) of different formulations were 
added to each well, and the plates were incubated again for 
60, 120, 180, 240, and 360 minutes. As a positive control, 
cell uptake with blank liposomes was performed according 
to the manufacturer’s protocol. All cell uptake experiments 
were performed in triplicate. The cells were transferred to 
an inverted fluorescence microscope (DMI 4000B; Leica 
Microsystems, Wetzlar, Germany) for imaging. Cell uptake 
efficiency was detected by the analysis of FITC-BSA activity. 
At different times, the cells were washed three times with 
PBS and then detached using 0.05% trypsin/0.02% EDTA, 
washed with PBS, and resuspended in 1 mL of PBS for flow 
cytometric analysis. The final results were reported in terms 
of fold increase over the blank liposomes.
statistical analysis
Data were expressed as the mean ± standard deviation 
(SD), and statistical analysis was carried out employing 
the   Wilcoxon statistics and Student’s t-test using SPSS 
software (SPSS, Chicago, IL) to assess the differences 
between experimental groups. P , 0.05 was taken as being 
statistically significant.
Results
Preparation and characterization  
of the liposome system
Stability studies were carried out on drug-free liposome for-
mulations over a period of 28 days. Table 1 shows the effect 
the ratios of different molar lipids (DSPC/cholesterol/DSPE-
PEG2000/DHA) and the ratios of lipid, ethanol, and water 
in the formula had on the particle size and zeta potentials of 
particles produced by the ethanol injection extrusion method. 
The liposome particle size varied between 121 and 157 nm, 
and the zeta potential varied between −42 and −30 mV . At the 
same ratios of L/E/W, the effects of varied ratios of DSPC/
cholesterol/DSPE-PEG2000 (A vs B; C vs D) were evaluated. 
The more DSPC in the formula, the smaller the particle 
size and the less the particle size changed over 28 days. At 
the same ratios of DSPC/cholesterol/DSPE-PEG2000, the 
effects of varied ratios of L/E/W (A vs C) were evaluated. The 
higher the lipid content, the smaller the particle size and the 
less the particle size changed over the 28 days. The lower 
the lipid content, the closer to neutral the zeta potential was. 
With a further increase in the ratios of L/E/W from 75/1/6 to 
75/1/9 (E), an increased stability in zeta potential and size 
was achieved.
Formulations E and F were selected in order to follow 
the variation in vesicle size over 190 days at 4°C; the mean 
particle size and zeta potential are presented in Figure 1. As 
shown in Figure 1, regardless of the change in particle size 
or zeta potential, the E formulation (Figure 1A) was more 
stable than the F formulation (Figure 1B). The liposome 
size of formula E (2–7 nm) remained nearly unchanged over 
1 month, as no significant differences were observed over 
this period. This indicated that after storing for 1 month, 
separation and stratification did not occur in the aqueous 
liposome suspensions.
We varied the DHA content (5%–30%), replacing DSPC 
in the formula, and the change in particle size and zeta poten-
tial was evaluated in the different formulas: DSPC/choles-
terol/DSPE-PEG2000/DHA of E (0% of DHA), E5 (5% of 
DHA), E15 (15% of DHA), and E30 (30% of DHA). The for-
mula containing 15% DHA (E15) resulted in the most stable 
particle size and zeta potential over 28 days. Therefore, we 
Table 1 The stability effect of different lipid molar ratios and L/e/W ratio formulas following the ethanol injection extrusion method
No Lipid  
molar  
ratioa
L/E/W  
ratiob
Particle size (nm) Zeta potential (mV)
0 (day)  
mean ± SD  
(CV%)c
7 (day)  
mean ± SD  
(CV%)
28 (day)  
mean ± SD  
(CV%)
0 (day)  
mean ± SD  
(CV%)
7 (day)  
mean ± SD  
(CV%)
28 (day)  
mean ± SD  
(CV%)
A 59/36/5/0 75/1/6 121 ± 5 (4) 121 ± 7 (6) 112 ± 4 (4) −42.8 ± 0.7 (1.6) −35.2 ± 1.2 (3.4)*** −20.1 ± 0.7 (3.6)***
B 39/57/4/0 75/1/6 131 ± 3 (3) 110 ± 6 (5)** 114 ± 10 (9)* −30.5 ± 2.3 (7.5) −27.2 ± 1.3 (4.8)* −55.5 ± 8.0 (14.3)***
C 59/36/5/0 50/1/6 138 ± 5 (4) 131 ± 6 (5) 120 ± 16 (13) −30.6 ± 3.7 (12) −18.1 ± 0.4 (2.4)*** −11.3 ± 2.1 (18.8)***
D 39/57/4/0 50/1/6 157 ± 23 (14) 162 ± 6 (4) 110 ± 16 (14) −34.2 ± 1.2 (3.4) −26.0 ± 1.4 (5.2)*** −17.2 ± 0.6 (3.4)***
e 59/36/5/0 75/1/9 124 ± 8 (6) 117 ± 14 (12) 122 ± 1 (1) −31.8 ± 2.1 (6.7) −31.8 ± 2.1 (6.7) −37.5 ± 2.1 (5.6)
F 39/57/4/0 75/1/9 119 ± 11 (9) 126 ± 6 (5) 128 ± 5 (4) −29.7 ± 0.5 (1.6) −27.7 ± 1.2 (4.4)** −28.3 ± 0.7 (2.4)***
e5 54/36/5/5 75/1/9 140 ± 5 (4) 137 ± 3 (2) 121 ± 3 (2)** nd nd nd
e15 44/36/5/15 75/1/9 115 ± 5 (4) 118 ± 4 (3) 119 ± 11 (9) −35.6 ± 4.9 (13.8) −35.5 ± 4.0 (11.3) −35.8 ± 1.4 (3.9)
e30 29/36/5/30 75/1/9 120 ± 8 (7) 129 ± 7 (5) 150 ± 14 (9)* nd nd nd
Notes: aIndicates lipid molar ratio of DsPC (distearoylphosphatidylcholine)/cholesterol/DsPe-Peg2000 (distearoylphosphoethanolamine-Peg2000)/DhA (docosahexaenoic 
acid); bindicates (lipid [mg]/ethanol [mL]/dd-water [mL]); cmean ± standard deviation (% coefficient of variation); *P <0.05; **P <0.01; ***P <0.001.
Abbreviations: L/e/W, lipid content/ethanol/water; sD, standard deviatio; nd, no detection.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and zeta potential of the E15 formulation remained nearly 
unchanged over 1 month (Table 1), as no significant dif-
ferences in size (2–4 nm) or zeta potential (0.1–0.3 mV) 
were observed over this period. The E15 suspensions were 
further assayed for changes in vesicle size over 90 days at 
4°C. The mean particle size and zeta potential from this test 
are presented in Figure 1C. These results, which we also 
confirmed via TEM and FE-SEM analysis, demonstrated the 
high stability of these liposome suspensions.
Preparation and characterization  
of lipoparticle system
The effects of FITC-BSA-loaded liposomes and lipoparticles 
prepared by ethanol injection (I) or the ethanol injection 
extrusion (IE) on particle size, zeta potential, particle yield, 
and entrapment efficiency before and after lyophilization 
are presented in Table 2. It was observed that both FITC-
BSA-loaded liposomes and lipoparticles prepared by ethanol 
injection demonstrated a significantly decreased particle size 
from about 200 nm to 130 nm. Comparing the optimal stabil-
ity between liposomes and lipoparticles, it was shown that 
the lipoparticle formula was more stable than the liposome 
formula over 30 days, as the zeta potential of liposomes was 
significantly changed from −13.7 to −8.6 mV (P , 0.05) 
(Figure 1D). However, the particle size and zeta potential 
of the lipoparticles were not significantly changed over the 
30 days (Figure 1D). Figure 2E shows the typical particle 
size distribution of lipoparticles after extrusion (FITC-BSA-
loaded lipoparticle-IE). A very low polydispersity index of 
less than 0.2 was recorded for all the formulations, indicating 
a narrow size distribution of vesicles. The vesicle size of the 
various formulations was recorded to be 215 ± 2 nm (n = 3), 
as calculated using a particle size analyzer, for protamine/
FITC-BSA 20/1 of FITC-BSA-loaded lipoparticles prepared 
by ethanol injection. The particle size was significantly 
reduced after passing through a 100 nm membrane dur-
ing the ethanol injection method. The vesicle size of the 
lipoparticles prepared by ethanol injection was recorded to 
be 134 ± 9 nm.
The spherical structure of the protamine/FITC-BSA com-
plex (core and lipoparticle) was further confirmed by TEM 
and FE-SEM analysis (Figure 2B and D). According to the 
TEM and FE-SEM micrographs, FITC-BSA particles ranged 
in size from 100 to 130 nm, correlating well with the measure-
ments obtained by the particle size analyzer. The TEM images 
of the FITC-BSA-liposomes (Figure 2A) and FITC-BSA-
lipoparticles (Figure 2B) indicated that both the liposomes 
and lipoparticles were almost spherical and had a smooth 
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Figure 1 The mean particle size () and zeta potential (•) stability tests for liposome 
suspensions as a function of time (stored at 4°C). (A) Formula No. e and (B) formula 
No.  F.  (C)  FITC-BsA-loaded  lipoparticles.  (D) Comparison of FITC–BsA-loaded 
liposomes and lipoparticles.
Note: *Compared to 0 day, P , 0.001 (paired t-test) (n = 3).
Abbreviation:  FITC-BSA,  fluorescein  isothiocyanate-conjugated  bovine  serum 
albumin.
found that the optimal preparation conditions were as follows: 
a ratio of DSPC/cholesterol/DSPE-PEG2000/DHA in weight 
of 44/36/5/15 and a proportion of L/E/W in volume of 75/1/9. 
Under these conditions, the liposomes had a small particle 
size and high stability, the mean diameter was 115 ± 5 nm, 
and the zeta potential was −35.6 ± 4.9. The liposome size International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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surface. The FE-SEM images of the FITC-BSA-liposomes 
(Figure 2C) and FITC-BSA-lipoparticles (Figure 2D) revealed 
nanometric- and quasispherical-shaped particles, respectively. 
No protein crystals were visible in the TEM or FE-SEM 
images of the FITC-BSA-loaded liposomes or lipoparticles. 
Also, no notable differences were found in morphology or 
size between the liposomes and lipoparticles.
Comparing the FITC-BSA encapsulation efficiency (%), the 
FITC-BSA-liposomes prepared by the ethanol injection method 
had an estimated encapsulation efficiency of 19.0% ± 4.0%, 
but the encapsulation efficiency for the FITC-BSA-loaded 
A
B D
C
E
FE-SEM of blank liposomes
FITC-BSA-loaded lipoparticles FITC-BSA-loaded lipoparticles
TEM of blank liposomes
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Figure 2 TeM image (left) and Fe-seM image (right) with 1% uranyl acetate negative staining. (A) FITC-BsA-loaded liposomes and (B) FITC-BsA-loaded lipoparticles.   
(C) FITC-BsA-loaded liposomes and (D) FITC-BsA-loaded lipoparticles. The scale bar is 100 nm. (E) Particle size distribution of FITC-BsA-loaded lipoparticles containing 
a protamine/FITC-BsA core.
Abbreviations: TEM, transmission electron microscope; FE-SEM, field-emission scanning electron microscope; FITC-BSA, fluorescein isothiocyanate-conjugated bovine 
serum albumin.
lipoparticles (with a core particle ratio of 20/1) prepared 
by the ethanol injection method was significantly higher at 
48.4% ± 19.7%. Our results showed that using the protamine/
FITC-BSA as a core to prepare lipoparticles significantly 
increased the encapsulation efficiency by the ethanol injec-
tion method. This indicated that FITC-BSA/protamine 
was effectively entrapped into lipoparticles during formu-
lation. When the same formula and preparation process was 
used to prepare lipoparticles or liposomes with or without pass-
ing through the 100 nm membrane, it was clear that the use of 
the extrusion method significantly increased the   encapsulation International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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efficiency and particle yield, with liposomes demonstrating 
an increased encapsulation efficiency from 19.0% to 51.4% 
and an increased yield from 69.4% to 77.4%; the lipoparticles 
demonstrated an increased encapsulation efficiency from 48.4% 
to 59.6% and an increased yield from 39.0% to 72.4%. Zeta 
potential analysis, as shown in Table 2, comparing liposomes 
with lipoparticles indicated that the zeta potential of liposomes 
was negative (−13.7 mV) and that of lipoparticles was positive 
(13.0 mV). As expected, adding positively charged protamine 
as a core material resulted in positive zeta potentials of the 
FITC-BSA/protamine complexes as well as the lipoparticles.
It was observed that lyophilization increased the particle 
size between 8% and 47% (Table 2). The change in particle 
size before and after lyophilization was not significantly 
different between the formulations, with the exception 
of the blank liposomes prepared by the ethanol injection 
method and the FITC-BSA-loaded liposomes prepared by 
the ethanol injection extrusion method. The particle size 
was shown to be larger when prepared by ethanol injection 
compared to the ethanol injection extrusion method (17% vs 
10%, respectively), and FITC-BSA-loaded liposomes were 
larger than lipoparticles (47% vs 10%, respectively). After 
freeze-drying, the particle size and the release profile of 
the reconstituted lipoparticles did not significantly change 
over the 4-month storage period compared to that of the 
freshly prepared lipoparticle suspensions, which indicated   
that the freeze-drying process increased the stability of the 
lipoparticles. However, different cryoprotectants and their 
methods of use need to be investigated to further improve 
the freeze-drying conditions.
As such, the optimal conditions for the modified ethanol 
injection extrusion method were as follows: the ratio of 
DSPC/cholesterol/DSPE-PEG2000/DHA in weight was 
44/36/5/15; the proportion of L/E/W in volume was 75/1/9; 
and the ratio of protamine/FITC-BSA in weight was 20/1. 
Under these conditions, the lipoparticles had a small particle 
size and high encapsulation efficiency, their mean diameter 
was 134 ± 9 nm, their zeta potential was 13 ± 1.6, the yield 
was 72.4%, and the encapsulation efficiency was 59.6%.
The protein retention profiles  
of lipoparticles and liposomes
Protein release was investigated by studying the release 
of encapsulated FITC-labeled BSA from lipoparticles and 
comparing it with that of liposomes. Figure 3 illustrates the 
retention profile of encapsulated FITC-BSA, indicating a 
prolonged retention time for lipoparticles as compared to 
liposomes. The effect of lyophilization on the lipoparticle 
retention profile was not significant, but the freeze-dried 
liposomes had an obviously reduced ability to retain FITC-
BSA (A vs C; Figure 3). The initial burst release of FITC-
BSA was followed by a continued and controlled release 
Table 2 The characteristics of FITC-BsA-loaded liposomes and lipoparticles
Formula Particle size( nm) Zeta potential  
(mV)
Yield (%)d EE(%)e
Before lyoa After lyob Dc  
% Meanf CV%g Mean CV% Mean CV% Mean CV% Mean CV%
Blank liposome-I 219 ± 3 2 281 ± 19* 7 25  − 35.5 ± 3.9 11.1 90.0 ± 5.3 6 –
Blank liposome-Ie 125 ± 2 19 177 ± 21* 12 41  − 12.4 ± 1.5 12.0 75.6 ± 10.7 14 –
FITC-BsA-liposome-I 202 ± 5 24 218 ± 10 4 8 −17.26 ± 2.9 16.5 69.4 ± 4.7 7 19.0 ± 4.0 20.9
FITC-BsA-liposome-Ie 126 ± 5 13 186 ± 24* 13 47  − 13.7 ± 1.4 10.2 77.4 ± 3.2 4 51.4 ± 6.1 11.8
FITC-BsA-lipoparticle-I 215 ± 2 31 252 ± 25 10 17      3.2 ± 0.4 13.9 39.0 ± 19.9 51 48.4 ± 19.7 40.7
FITC-BsA-lipoparticle-Ie 134 ± 9 19 148 ± 10 7 10    13.0 ± 1.6 12.3 72.4 ± 15.7 22 59.6 ± 0.4 0.7
Notes: a,bLiposomes particle size before/after lyophilization; cdifference in liposome particle size before and after lyophilization,
 
D%
(lyobefor lyoafter)
lyobefor
100%; =
∆−
×
d
Yield%
MASSlipo
MASSinitial
100%; =×
e
EE%
(FITCB SAenca)
(FITCB SAtotal)
100%, =
−
−
×
where MAsslipo is the mass of the lyophilized liposome powder, MAssinitial is the mass of the total materials, FITC-BsAenca is the amount of adsorbed FITC-BsA measured in 
the liposomes; FITC-BsAtotal is the initial amount of FITC-BsA, lyobefore is the particle size before lyophilization, lyoafter is the particle size after lyophilization; fmean ± standard 
deviation, n = 3; g% coefficient of variation = sD/mean × 100%. *Compared to before lyophilization, P < 0.05 (paired t-test).
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phase from both particles up to 1 day. The FITC-BSA burst 
release of 56.4% (liposomes) and about 20% (lipoparticles) 
was observed within 0.5 hours, and this was followed by a 
slow and sustained release of 96% (liposomes) and about 
90% (lipoparticles) by day 1.
Table 3 presents the in vitro FITC-BSA retention rate 
constants based on three different mathematical models for 
FITC-BSA particles. The retention of FITC-BSA in particu-
late systems involves three different mechanisms: (a) release 
from the surface of particles (burst release), (b) diffusion 
through the swollen matrix, and (c) release due to particle 
erosion. In the majority of cases, drug release from particles 
follows more than one type of mechanism. The best fitting 
mathematic model was Higuchi model (R2 . 0.93), and the 
calculated rate constant k′h was −0.1953 and −0.1879 hr-0.5 
for freshly prepared liposomes and lipoparticles,   respectively, 
and 0.2332 and −0.2172 hr-0.5 for freeze-dried liposomes and 
lipoparticles, respectively. The effect of lyophilization and 
the time to 50% release (t50%) of FITC-BSA-particles 
calculated by the Higuchi model are shown in Figure 4. 
No obvious difference in (t50%) was observed before and after 
freeze-drying of FITC-BSA particles. However, the (t50%) 
of lipoparticles (7.9 hours) was significantly longer than the 
(t50%) of liposomes (3.3 hours). This may be attributed to the 
strong ionic interaction between the counter-ion of FITC-BSA 
and protamine in the lipoparticles.
Figure 5 shows the SDS-PAGE analysis of protamine/
FITC-BSA particles, FITC-BSA-liposomes, and FITC-
BSA-lipoparticles before and after lyophilization after 
4 and 8 hours of incubation. Bands representing pure as 
well as extracted antigen at various stages are clearly visible, 
indicating that the encapsulated FITC-BSA was unaltered. 
The results suggested that FITC-BSA was successfully 
encapsulated and remained stable at all stages.
Figure 6 indicates the cytotoxicity of varied concentra-
tions of FITC-BSA-loaded liposomes and lipoparticles 
against the human epithelial colorectal adenocarcinoma cell 
line Caco-2, as based on WST-1 analysis. The percentage of 
0
100 FBSA-20lipoparticle
FBSA-liposome FBSA-liposome
FBSA-20lipoparticle
FBSA-liposome
FBSA-20lipoparticle
Time (hours)
FBSA-liposome
Time (hours)
R
e
t
e
n
t
i
o
n
 
o
f
 
F
I
T
C
-
B
S
A
 
(
%
)
R
e
t
e
n
t
i
o
n
 
o
f
 
F
I
T
C
-
B
S
A
 
(
%
)
C
u
m
u
l
a
t
i
o
n
 
r
e
t
e
n
t
i
o
n
R
e
t
e
n
t
i
o
n
 
a
m
o
u
n
t
(
µ
g
F
I
T
C
-
B
S
A
/
m
g
 
l
i
p
o
p
a
r
t
i
c
l
e
)
(
µ
g
F
I
T
C
-
B
S
A
/
m
g
 
l
i
p
o
p
a
r
t
i
c
l
e
)
Time (hours) Time (hours)
FBSA-20lipoparticle
80
60
40
20
0
100
80
60
40
20
0
51 01 52 02 5 0
8
6
4
2
0
0
0
0
2
4
6
8
51 01 52 02 5
51 01 52 02 5
51 01 52 02 5
A B
C D
Figure 3 The remaining amount of FITC-BSA from the release profile of FITC-BSA-loaded liposomes and lipoparticles in PBS (pH 7.4) at 37°C. (A and C) Before lyophilization 
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viable cells was greater than 85% after treatment with FITC-
BSA-loaded liposomes and greater than 95% after treatment 
with FITC-BSA-loaded lipoparticles at concentrations of 
0.25, 0.025, and 0.0025 mg/mL. The higher percentage 
of cell viability relative to controls at these concentrations 
indicated that the FITC-BSA-loaded particles were not cyto-
toxic towards Caco-2 cells under these conditions. It should 
be noted that under the conditions used, no aggregation of 
particles was observed.
The FITC-BSA-loaded particles were endocytosed 
efficiently (Figure 7). A total of 200 µL of suspension of dif-
ferent formulations (0.01 mg/mL) was added to Caco-2 cells. 
The cells were then harvested and analyzed for FITC-BSA 
uptake by flow cytometer analysis in order to investigate 
retention/absorption and to provide further information on 
the cellular response to particle incubation. The control cells 
were evenly spread and maintained their typical shape and 
surface morphology. The test cells were found to absorb 
the nanoparticles to an acceptable extent. For all particles, 
after 1 hour of incubation, the cells presented with brightly 
dotted fluorescence within the membrane of viable cells; 
this was retained for up to 6 hours. At 1 hour, the uptake 
of FITC-BSA was significantly greater (12-fold; P , 0.01) 
for the FITC-BSA-loaded lipoparticles than the FITC-BSA-
loaded liposomes (Figure 7), indicating that lipoparticles 
100–200 nm in size acquire the best properties for cellular 
uptake. The distribution of fluorescence in the cytoplasm of 
Caco-2 cells may be partly due to the high level of FITC-
BSA released from the lipoparticles. These results indicate 
that the lipoparticles were endocytosed into the cells and that 
the FITC-BSA-loaded lipoparticles had increased penetration 
into Caco-2 cells relative to the liposomes.
Discussion
The aim of this study was to develop a novel preparation 
strategy for liposomes for use as carriers for the delivery of 
macromolecules. The preparation strategy was based on the 
principles of the ethanol-injection method and used a mem-
brane contactor optimized for liposome production. There 
were many factors affecting the particle size of liposomes. 
In all the experiments (Table 1), the dispersed phase (ie, 
phospholipids and cholesterol in ethanol) passed very quickly 
through the membrane (5–10 seconds). In this work, the flux 
was not measured vs time; thus, no exact fouling data were 
available. However, the very high average fluxes, combined 
with the fact that the phospholipid concentrations had no 
effect on the experiment duration, suggested that fouling was 
probably very low for these experimental conditions. This 
might be explained by the relatively low concentration of 
phospholipids in the dispersed phase and the mean membrane 
pore size, which was, in all cases, less than 150 nm. The 
experiment using the 100 nm membrane and a phospholipid 
concentration of 0.15 mM was repeated ten times in order to 
study the reproducibility of this technique. The pressure of 
the organic phase, the volume of both phases, as well as the 
aqueous phase flow rate were kept constant. In our study, the 
preparation methods had a greater influence on particle size 
than the formulation of the liposomes. A similar result was 
reported by Elbayoumi et al,18 using lipid film hydration to 
prepare liposomes, which were extruded through 200 nm and 
Table 3 retention parameters for FITC-BsA-loaded particles 
obtained  after  fitting  in  vitrodrug  release  data  (0.5–24  hours) 
to three different mathematical models for FITC-BsA retention 
kinetics
Formulation Mathematical modelsa for retention 
kinetics
Zero order First order Higuchi  
model
Before lyophilization
  FITC-BsA-liposome k′0 = −0.0319 k′1 = −0.0556 k′h = −0.1953
r2 = 0.7838 r2 = 0.6688 r2 = 0.9307
  FITC-BsA lipoparticle k′0 = −0.0314 k′1 = −0.0882 k′h = −0.1879
r2 = 0.8543 r2 = 0.5940 r2 = 0.9669
After lyophilization
  FITC-BsA-liposome k′0 = −0.0377 k′1 = −0.0735 k′h = −0.2332
r2 = 0.7580 r2 = 0.5584 r2 = 0.9154
  FITC-BsA lipoparticle k′0 = −0.0374 k′1 = −0.0965 k′h = −0.2172
r2 = 0.9306 r2 = 0.7183 r2 = 0.9922
Notes: aZero order, Mt/M⊥ = k′0t; first order, Mt/M⊥ = 1 − exp(−k′1 t); higuchi model, 
Mt/M⊥ = k′h t1/2, where Mt/M⊥ is the fraction of the drug retained at time t and k′0, k′1, 
and k′h, represent the zero-order release constant, first-order retention constant, 
and higuchi constant, respectively.
Abbreviation:  FITC-BSA,  fluorescein  isothiocyanate-conjugated  bovine  serum 
albumin.
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then 100 nm pore-size nucleopore polycarbonate membranes 
to obtain uniform vesicles of about 130 nm in size.
Eckert et al28 reported that liposomal DHA is able to 
restore or maintain physiological membrane properties, 
which are required for neuroprotective sAPPα secretion and 
autocrine modulation for neuronal survival. Polyunsaturated 
fatty acids (PUFA) are essential for regulating the fluidity 
of cell membranes, and there are several lines of evidence 
that this fluidity is important for the modulation of amyloid 
precursor protein processing. In the present study, we added 
DHA in the formulation, which represents the most abundant 
PUFA in the brain and is implicated in various functions, 
including mediation of membrane–protein interactions, gene 
expression, neurogenesis, and learning.
When encapsulating the hydrophilic proteins into the 
liposomes, only 19% of the FITC-BSA was entrapped in the 
liposome suspension. In an effort to overcome the limitation 
of encapsulation efficiency, instability, and early release of 
entrapped bioactive proteins from liposomes, we designed 
and tested lipoparticles. Lipoparticles are advanced lipo-
somal constructs bearing a core of biocompatible protamine 
with FITC-BSA, which serves as a functional skeleton and 
provides mechanical support for the lipid vesicle. A high 
efficiency of encapsulation of FITC-BSA into lipoparticles 
(59.7%) was obtained by preparing protamine-containing 
FITC-BSA nanoparticles entrapped in phospholipids. This 
high encapsulation efficiency of FITC-BSA into lipoparticles 
was believed to be due to the solid core containing protamine/
FITC-BSA and, therefore, to the increased coating ability 
of the phospholipids. Protamine, which has been shown to 
extend the release period of the chelate both in vitro and in 
vivo with protein in regular clinical use, was used for the 
design of novel membrane-translocating/nuclear-localizing 
pharmaceuticals whose development was initiated with 
other membrane-translocating peptides.29,30 In addition, the 
protamine in solid lipid nanoparticles is a biodegradable par-
ticulate drug delivery system. Only a few investigations have 
studied the incorporation of proteins into lipoparticles and 
little research has been reported on drug release from protein-
loaded lipoparticles. As expected, the release of protein from 
lipoparticle systems was slower than from liposomes only. In 
the lipoparticle system, a very small burst release (from the 
surface of the particles) of about 20% was observed within 
0.5 hours, and then slow and sustained release of about 90% 
was observed at 24 hours (diffusion through the swollen 
rubbery matrix, and release due to polymer erosion). This 
may be attributed to the strong ionic interaction between the 
counter-ion of FITC-BSA and protamine. The core polymer 
structure made the lipoparticle more stable and promoted 
continued and controlled release via diffusion release and/
or swelling release. The liposome system showed a 56.4% 
initial burst at 0.5 hours. The higher level of burst release 
from liposomes may be due to the decreased concentration 
of positively charged groups, which causes the ionic interac-
tion between the counter-ion of FITC-BSA and the lipid to 
weaken. To examine the mechanism of drug release from 
our formulation, we analyzed three different kinetic models. 
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Figure 5 Protein stability evaluation by sDs-PAge (M, molecular weight markers; 1, BsA; 2, FITC-BsA; 3, FITC-BsA particle; 4, FITC-BsA liposome; 5, FITC-BsA lipoparticle-I; 
6, FITC-BsA lipoparticle-Ie; 7, Freeze-dried FITC-BsA lipoparticle-Ie; 8, FITC-BsA lipoparticle-Ie in 13.7 mM PBs for 4 hours; and 9, FITC-BsA lipoparticle-Ie in 13.7 mM 
PBs for 8 hours).
Abbreviations: SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; FITC-BSA, fluorescein isothiocyanate-conjugated bovine serum albumin.
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In PBS solution, the Higuchi model was the best fit with 
the release kinetics data for FITC-BSA from liposome and 
lipoparticles, respectively. It seems that the process of FITC-
BSA release is mainly controlled by the diffusion process. 
Further research along these lines might be useful to further 
our understanding of this important pharmaceutical.
Recently, particular emphasis has been placed on the 
measures that protect membrane integrity during lyophiliza-
tion. Lyoprotective mechanisms, such as water replacement 
and vitrification models, have been known for the past few 
decades and are well recognized. These measures mainly 
focus on the protection of the lipid bilayers from damage 
by ice crystals during freezing, inhibition of vesicle fusion/
aggregation following dehydration, and the avoidance of 
a phase transition during rehydration. These problems are 
closely related to the choice of formulation and technological 
parameters during lyophilization. More importantly, the 
choice of less than optimal parameters will result in failure 
of the final freeze-dried cakes. Hence, many factors affecting 
these above processes, such as the selection of lyoprotectants, 
12 0
0
4
8
12
16
Time (hours)
F
o
l
d
 
i
n
c
r
e
a
s
e
 
o
v
e
r
 
n
o
n
-
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
4 6
Data.026 
0  200  400  600 
FSC-H 
800  1000 
Dot map  0 hours 1 hours
6 hours 4 hours 2 hours
100 
0
4
0
8
0
1
2
0
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
 
1
6
0
2
0
0
0
4
0
8
0
1
2
0
1
6
0
2
0
0
0
4
0
8
0
1
2
0
1
6
0
2
0
0
0
4
0
8
0
1
2
0
1
6
0
2
0
0
0
4
0
8
0
1
2
0
1
6
0
2
0
0
101  102 
FL1-H  FL1-H 
FL1-H 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
S
S
C
-
H
 
C
o
u
n
t
s
 
FL1-H  FL1-H 
103  104  100  101  102  103  104 
100  101  102  103  104  100  101  102  103  104  100  101  102  103  104 
M1
M1
M2 M2
M1 M1
M2
M2
M1
M2 M2
**
**
AB
C
RI
Figure 7 Caco-2 cell uptake profiles of FITC-BSA-loaded lipoparticles (blank) and liposomes (black). Data represents mean ± sD, n = 3. (A) Forward and side light scatter 
was used to gate the desired scattering events (normal cells) from dead cells and cell debris. (B) Uptake of FITC-BsA-loaded Pegylated liposomes and lipoparticles into 
Caco-2 cells. Cells were analyzed with 488 nm excitation and 522 nm band-pass filters in the emission path. (C) Fluorescence intensity of FITC-BsA-loaded liposome and 
lipoparticle preparations in normal cells expressed as the intensity ratio by dividing by the untreated control.
Notes: Data are expressed as mean ± sD, n = 3 (student’s t-test; ** P , 0.01).
Abbreviations: FITC-BSA, fluorescein isothiocyanate-conjugated bovine serum albumin; SD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2416
Chang et al
liposome bilayer composition, and freeze-drying protocols, 
need to be optimized.22 The particle size of the reconstituted 
liposomes or lipoparticles were also affected by many factors, 
such as the cryoprotectant, freeze-drying time, particle size 
of the freshly made liposomes, and other characteristics, of 
which the cryoprotectant is considered one of the most cru-
cial factors. Christensen et al23 compared the cryoprotective 
effects of trehalose and sucrose on DDA/TDB liposomes and 
reported that trehalose was a more efficient stabilizer than 
sucrose. In our study, the results showed that when trehalose 
was used as a cryoprotectant, the lipoparticles had a better 
response than liposomes.
The physicochemical properties of liposomes including 
size, charge, and release profile are the governing factors of 
stability. Storage stability of various liposomal formulations 
was evaluated at two different dosages, for both suspensions 
and lyophilized powder, at 4°C ± 1°C and 25°C ± 1°C. For 
lyophilized powder stored at 4°C ± 1°C for 90 days, 26% 
FITC-BSA leakage was detected from conventional liposomes 
while about 5% leakage was found for lipoparticles, indicating 
the higher in vitro stability of lipoparticles. Furthermore 
no change in lamellarity and no significant difference in 
vesicular size were observed following lipoparticle storage. 
Following SDS-PAGE analysis, clearly visible bands of pure 
as well as extracted antigen at various time intervals were 
obtained, showing that the encapsulated FITC-BSA protein 
was unaltered for up to 90 days. These results suggested 
that FITC-BSA was successfully encapsulated and remained 
stable at 4°C ± 1°C for 90 days. The freshly made liposome 
and lipoparticle suspensions and the freeze-dried liposomes 
and lipoparticles demonstrated highly stable properties 
when stored away from light at 4°C. As we expected, 
lipoparticles were stable after lyophilization with all of the 
advantages of liposomes, while eliminating the instability 
of liposomes, and with the added advantage of controlled 
release over a prolonged period of time. This indicates a good 
opportunity for their commercial use as delivery vehicles 
for recombinant proteins, monoclonal antibody, or nucleic 
acid-based products.
In order to study the cellular uptake of nanoparticles 
in vitro and in vivo, the use of fluorescently labeled 
nanoparticles is the most common experimental approach.31 
Due to its similar structural and functional differentiation 
to mature enterocytes, the Caco-2 monolayer model is 
an established in vitro tool for evaluating the intestinal 
permeability and metabolism of drugs.27 FITC-BSA makes 
cellular uptake of nanoparticles readily detectable by 
fluorescence microscopy.26 The extent of particle uptake was 
determined by flow cytometry and quantitative extraction 
of the markers from the cells. It has been proposed that the 
size of the particles plays a key role in their adhesion to 
and interaction with living cells.32 In general, it is assumed 
that particles up to about 100–200 nm can be internalized 
by receptor-mediated endocytosis, while larger particles 
have to be taken up by phagocytosis.33 The smaller-sized 
particles seem to have more efficient interfacial interactions 
with the cell membrane compared to larger-sized particles.27 
Therapeutic use of lipoparticles is of importance, since 
the small size of lipoparticles could improve efficacy of 
particle-based oral drug delivery systems and the smaller 
size could also improve the efficiency of cellular uptake, 
making these particles highly feasible for use in oral drug 
delivery therapy.
Conclusion
This study demonstrated that spherical and mono dispersions 
of FITC-BSA-loaded PEG-modified lipoparticles can 
be prepared by an ethanol injection extrusion method 
with spontaneous assembly, with protamine and FITC-
BSA as the protein core and a lipid formula containing 
distearoyl phosphatidylcholine/cholesterol/distearoyl 
phosphoethanolamine-PEG2000/docosahexaenoic acid. 
The PEG-modified lipoparticles demonstrated an average 
particle size of 133.7 ± 8.6 nm with a positive zeta potential of 
13.3 mV . The storage stability assays and SDS-PAGE results 
confirmed that the preparation process and products were 
still satisfactory for as long as 90 days. A high encapsulation 
efficiency (59.7%) of FITC-BSA was achieved, and the 
release profile of FITC-BSA from the lipoparticles indicated 
a small burst release followed by a continued and controlled 
release. The protein retention of the lipoparticles was twice 
as long as that of liposomes. The cytotoxicity and cellular 
uptake assays indicated that the PEG-modified lipoparticles 
were less toxic to cells and were more efficient at delivery into 
the cells than liposomes. In conclusion, this new lipoparticle 
system offers interesting potential as a carrier for proteins 
and hydrophilic compounds.
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